Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)
NCT ID: NCT03608657
Last Updated: 2024-06-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
102 participants
OBSERVATIONAL
2018-07-31
2022-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients will be enrolled from the practices of predominantly community rheumatologists and will be followed for 12 months from the time of initiation of treatment with Otezla® In line with the observational nature of the study, there will be no protocol imposed tests or assessments. However, recommended follow up visits will be at 4, 8 and 12 months. In addition, patients may be asked to voluntarily complete self-administered questionnaires.
The 24-month assessment will be aimed to determine whether or not treatment with Otezla® has been maintained, and if not, to ascertain the reason for discontinuation and what new treatment was initiated following discontinuation of Otezla®
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
NCT01925768
Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
NCT00456092
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
NCT01172938
Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in Greece
NCT03780504
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
NCT03757013
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Psoriatic Arthritis patients treated with Apremilast
Active PsA as per the CASPAR criteria, based on the investigator's clinical judgement with access to commercially available Otezla
Apremilast
Apremilast
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Apremilast
Apremilast
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult patients (≥18 years of age) with PsA
* Prescribing physician has decided to initiate treatment with Otezla®, and this decision was prior to and independent of patient enrollment in the study.
* Access to commercially available Otezla®
Exclusion Criteria
* Participation in Investigational Clinical Trial within the last 60 days.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Waterside Clinic
Barrie, , Canada
The Arthritis and Osteoporosis Centre
Burlington, , Canada
Adachi Medicine Professional Corporation
Hamilton, , Canada
Credit Valley Rheumatology
Mississauga, , Canada
Institut de Recherche en Rhumatologie de Montréal
Montreal, , Canada
Applied Medical Informatics Research Inc. (A.M.I.R.)
Montreal, , Canada
Brent Appleton Clinic New Westminster
New Westminster, , Canada
Dr. A. M. Jaroszynska Rheumatology and Osteoporosis Clinic
Oakville, , Canada
Drs M&W Teo
Penticton, , Canada
Groupe de recherche en maladies osseuses Inc.
Québec, , Canada
Centre de Rhumatologie de l'Est du Quebec
Rimouski, , Canada
Polmed Research Inc.
Saskatoon, , Canada
Clinique Jacques Cartier
Sherbrooke, , Canada
St. Clare's Mercy Hospital
St. John's, , Canada
Dr. Juris Lazovskis Incorporated
Sydney, , Canada
Toronto Western Hospital, University Health Network
Toronto, , Canada
Arthur Karasik Medicine Professional Inc.
Toronto, , Canada
Dr. Jonathan D. Chan Inc.
Vancouver, , Canada
Dr. Sabeen Anwar Medicine Professional Corporation
Windsor, , Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Chandran V, Bessette L, Thorne C, Sheriff M, Rahman P, Gladman DD, Anwar S, Jelley J, Gaudreau AJ, Chohan M, Sampalis JS. Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study. Rheumatol Ther. 2024 Apr;11(2):443-455. doi: 10.1007/s40744-024-00641-w. Epub 2024 Feb 28.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Expanded Access for CC-10004
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1214-0693
Identifier Type: OTHER
Identifier Source: secondary_id
CC-10004-PSA-011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.